Triple
T7930815
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | AbbVie |
E184183
|
entity |
| Predicate | notableProduct |
P1448
|
FINISHED |
| Object |
Venclexta
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
|
E697099
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69ca8290c21c8190906a5ca6fe2b03c4 |
elicitation | completed |
| NER | batch_69cb3accc388819087065ebe7d5d9591 |
ner | completed |
| NED1 | batch_69cb5c01602081908ea1af24785260ff |
ned_source_triple | completed |
| NED2 | batch_69cb76d2dff8819085ad9e10baad1537 |
ned_description | completed |
| NEDg | batch_69cb5f22f89c8190a98208bf096a2427 |
nedg | completed |
Created at: March 30, 2026, 5:07 p.m.